19 February 2018 - Vertex has presented NHS England with an “innovative long-term framework proposal” that hopes to secure access for all eligible patients to its current and future portfolio of cystic fibrosis medicines.

Specifics of the offer haven’t been revealed at this stage, but according to the firm the approach should ensure timely access to its medicines while providing budget certainty and value to the NHS.

Crucially, it “offers fair and equal access for cystic fibrosis patients to precision medicines that are tailored to specific genetic mutations,” a spokesman said.

Read Pharma Times article